TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Able to comprehend and willing to sign an informed consent form.~2. Male and female subjects between 30 and 83 years old, inclusive.~3. Diagnosed with idiopathic PD according to the UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria for at least 3 years.~4. Disease severity Stages I-III (modified Hoehn \&Yahr staging) at ON.~5. Treated with L-DOPA/DDCI for at least 1 year with clear clinical improvement.~6. Treated with 3 to 8 daily doses of L-DOPA/DDCI, which can include a slow-release formulation.~7. On a stable regimen of L-DOPA/DDCI and other anti-PD drugs for at least 4 weeks before screening.~8. Signs of wearing-off phenomenon (end-of-dose deterioration) for a minimum of 4 weeks before screening with average total daily OFF time while awake of at least 1.5 hours, excluding the early morning pre-first dose OFF, despite optimal anti-PD therapy (based on the investigator's judgment.~Exclusion Criteria:~1. Non-idiopathic PD (atypical parkinsonism, secondary \[acquired or symptomatic\] parkinsonism, Parkinson-plus syndrome).~2. Dyskinesia disability score \>3 in the Unified Parkinson's Disease Rating Scale UPDRS) Sub-section IV A, item 33.~3. Severe and/or unpredictable OFF periods.~4. Treatment with prohibited medication: entacapone, tolcapone, neuroleptics, venlafaxine, MAO inhibitors (except selegiline up to 10 mg/day in oral formulation or 1.25 mg/day in buccal absorption formulation or rasagiline up to 1mg/day), or antiemetics with antidopaminergic action (except domperidone) within the month before screening.~5. Treatment with apomorphine within the month before screening or likely to be needed at any time during the study.~6. Dosage change of concomitant anti-PD medication within 4 weeks of screening.~7. Previous or planned (during the entire study duration, including the OL period)deep brain stimulation.~8. Previous stereotactic surgery (e.g. pallidotomy, thalamotomy) for PD or with planned stereotactic surgery during the study period.~9. Any investigational medicinal product within the 3 months (or within 5 half-lives, whichever is longer) before screening.~10. Any medical condition that might place the subject at increased risk or interfere with assessments.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 83 Years
- Healthy Volunteers: f

Study Arms:
- BIA 9-1067 25 mg once daily (QD). (Type: EXPERIMENTAL): BIA 9-1067, OPC, Opicapone 25 mg once daily (QD).
- BIA 9-1067 50 mg once daily (QD). (Type: EXPERIMENTAL): BIA 9-1067, OPC, Opicapone 50 mg once daily (QD).
- Placebo (Type: PLACEBO_COMPARATOR): PLC, Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy Compared With Placebo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must be undergoing primary unilateral first metatarsal bunionectomy that includes a distal Chevron osteotomy only, with or without the Akin procedure~* Patients must be healthy or medically stable on the basis of clinical laboratory tests performed at screening~* Women must be postmenopausal, surgically sterile, abstinent, or practicing or agree to practice an effective method of birth control and have a negative serum pregnancy test at screening and a negative urine pregnancy test before surgery~* If a male, must use an approved method of birth control and does not donate sperm from the day of study drug administration until 3 months afterwards~* Qualifying baseline Pain Intensity must be rated as greater than or equal to 4 on an 11-point (0 to 10) PI NRS, recorded within 30 minutes before randomization, no earlier than 10 hours after the first surgical incision and within 9 hours after termination of the continuous Popliteal Sciatic Block (PSB) infusion Exclusion Criteria: - History of seizure disorder or epilepsy, severe traumatic brain injury, episode(s) of unconsciousness of more than 24 hours duration, malignancy in the past 2 years with the exception of successfully treated basal cell carcinoma~* Mild or moderate traumatic brain injury, stroke, transient ischemic attack, or brain neoplasm within 1 year of screening~* Renal insufficiency, impaired hepatic function~* Use of anticonvulsants, monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), neuroleptics, serotonin norepinephrine reuptake inhibitors (SNRIs), selective serotonin reuptake inhibitors (SSRIs) or triptans

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Tapentadol IR 50 mg (Type: EXPERIMENTAL): None
- Tapentadol IR 75 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Two Doses of a Common Cold Treatment on Alertness

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
* Participants with symptoms of cold \< 96 hours, rating of at least '2' on malaise at least 4 other symptoms of cold.~* No history of clinically significant perennial rhinitis, no recent antibiotic, antihistamine or cold treatment, no caffeine in the previous 12 hours, no psychoactive medication in the 14 days prior to screening, no pregnancy, breastfeeding or participation in this trial, or another trial in the 30 days prior to screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- highest dose Paracetamol + caffeine (Type: ACTIVE_COMPARATOR): highest dose of Paracetamol and caffeine
- low-dose Paracetamol + caffeine (Type: ACTIVE_COMPARATOR): lowest dose of Paracetamol and caffeine
- high dose paracetamol (Type: ACTIVE_COMPARATOR): highest dose paracetamol
- low dose paracetamol (Type: ACTIVE_COMPARATOR): lowest dose paracetamol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria: - Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial - Male or female, age equal to or above 18 years at the time of signing informed consent - Subjects diagnosed with type 2 diabetes and on stable treatment in a period of 60 days prior to screening with metformin equal to or above 1500 mg (or maximum tolerated dose equal to or above 1000 mg). Stable is defined as unchanged medication and unchanged daily dose - HbA1c 7.0 - 10.5 % (53-91 mmol/mol) (both inclusive) Exclusion Criteria: - Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential not using an adequate contraceptive method throughout the trial including the 5 week follow-up period (adequate contraceptive measure as required by local regulation or practice) - Any disorder which, in the opinion of the investigator, might jeopardise subject's safety or compliance with the protocol - Treatment with glucose lowering agent(s) other than stated in the inclusion criteria in a period of 60 days before screening. An exception is short-term treatment (equal to or below 7 days in total) with insulin in connection with inter-current illness - History of chronic or idiopathic acute pancreatitis - Screening calcitonin value equal to or above 50 ng/L (pg/mL) - Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2) - Impaired renal function defined as estimated glomerular filtration rate (eGFR) below 60 ml/min/1.73 m\^2 per modification of diet in renal disease (MDRD) formula (4 variable version) - Acute coronary or cerebrovascular event within 90 days before randomisation - Heart failure, New York Heart Association (NYHA) class IV

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Semaglutide 0.5 mg OW + sitagliptin placebo OD (Type: EXPERIMENTAL): None
- Semaglutide 1 mg OW + sitagliptin placebo OD (Type: EXPERIMENTAL): None
- Sitagliptin OD + semaglutide placebo 0.5 mg OW (Type: ACTIVE_COMPARATOR): None
- Sitagliptin OD + semaglutide placebo 1 mg OW (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Side Effects of Bone Marrow Derived CD133 Transplantation in Cerebral Palsy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. A diagnosis of spastic quadriplegic CP~2. Children must be between the ages of 4 and 12 years~3. Children must be cleared by an orthopedic surgeon for risk of hip subluxation or dislocation and cannot have significant scoliosis (curvature \> 40 degrees)~4. Children must be seizure-free or seizure controlled~Exclusion Criteria:~1. Children who have a diagnosis of mixed types of CP (i.e. athetosis) or other movement disorders (i.e. ataxia)~2. Children who have had a selective dorsal rhizotomy, are presently are receiving intrathecal Baclofen, or have changed their spasticity medications in the past 6 months.~3. Children who have a metallic or electrical implants

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- stem cell recipients (Type: EXPERIMENTAL): The 4-12 years old patients with cerebral palsy who undergone bone marrow derived CD133 transplantation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Metformin in High Responder Polycystic Ovary Syndrome (PCOS) Patients Undergoing IVF Cycles

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* History of one previous cancelled cycle for high-risk of OHSS, or history of moderate/severe OHSS during their previous IVF cycle~* Infertility~* Polycystic ovary syndrome (PCOS)~* insulin resistance~* hyperandrogenism~Exclusion Criteria:~* BMI\>30 kg/m2~* age \>35 years~* FSH\>9UI/L

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Experimental group (Type: EXPERIMENTAL): Patients receiving metformin pretreatment and co-administration
- Control group (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Subject meets any of the following criteria and with sUA ≤10.0 mg/dL:~  1. sUA level of \>7.0 mg/dL at 7 days prior to baseline with gout;~ 2. sUA level of ≥8.0 mg/dL at 7 days prior to baseline without gout but with complications (hypertension, ischemic heart disease, diabetes, metabolic syndrome);~ 3. sUA level of ≥9.0 mg/dL at 7 days prior to baseline without gout and complications.~Exclusion Criteria:~* Subject with an acute gout flare that has not resolved at least 14 days prior to the baseline visit.~* Subject has a history or suspicion of kidney stones.~* Subject has an estimated creatinine clearance \<60 mL/min calculated by the Cockcroft Gault formula~* Subject is receiving strong or moderate CYP3A inhibitors

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- RDEA3170 1 (Type: EXPERIMENTAL): RDEA3170 5mg followed by RDEA3170 7.5mg
- RDEA3170 2 (Type: EXPERIMENTAL): RDEA3170 10mg followed by RDEA3170 12.5mg
- RDEA3170 3 (Type: EXPERIMENTAL): RDEA3170 12.5mg followed by RDEA3170 15mg
- RDEA3170 4 (Type: PLACEBO_COMPARATOR): RDEA3170 Placebo
- Allopurinol (Type: OTHER): Allopurinol 200mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reduction of Ischemic Myocardium With Ranolazine-Treatment in Patients With Acute Myocardial Ischemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Proof of acute cardiac ischemia by elevated serum Troponin T-hs levels \> 14 pg/nl~* Proof of myocardial dyskinesia with functional echocardiography (speckle tracking)~* Stable angina pectoris \>/= CCS II in patient history~* Stabilized (i.e. normalized vital parameters) patients after coronary angioplasty or angiography~* Coronary angioplasty or angiography not older than 24 hours~* Written informed consent~* Established standard therapy for coronary artery disease (i.e. Beta-Blocker, ACE-Inhibitor or AT1-Inhibitor, ASS, Clopidogrel, Statins)~Exclusion Criteria:~* Patients younger than 18 years of age~* Acute cardio-pulmonary decompensation~* Middle and high grade liver insufficiency (Child-Pugh Score B and C)~* High grade renal insufficiency (Creatinine-Clearance \< 30 ml/min)~* Concomitant treatment with potent inhibitors of CYP3A4~* Concomitant administration of class Ia (e.g. quinidine) or class III (e.g. dofetilide, sotalol) antiarrhythmics, except for amiodarone~* Concomitant administration of \> 20 mg simvastatin/day~* Patients with heart failure classification NYHA III and NYHA IV~* Homeless patients and drug-addicted patients~* Pregnant and/or breast-feeding women~* Treatment with Ranolazine prior to enrolment in RIMINI-Trial~* Allergy against Ranolazine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranolazine (Type: ACTIVE_COMPARATOR): Ranolazine 500mg bid orally 7 days Ranolazine 750mg bid orally 35 days
- No additional medication (Type: NO_INTERVENTION): No additional medication - control group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease (ENGAGE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The participant (and/or their parent/legal guardian) was willing and able to provide signed informed consent prior to any study-related procedures to be performed;~* The participant was at least 16 years old at the time of randomization;~* The participant had a confirmed diagnosis of Gaucher disease Type 1;~* Female participants of childbearing potential must had a documented negative pregnancy test prior to dosing. In addition all female participants of childbearing potential must use a medically accepted form of contraception throughout the study.~Exclusion Criteria:~* The participant has had a partial or total splenectomy;~* The participant had received pharmacological chaperones or miglustat within 6 months prior to randomization;~* The participant had received enzyme replacement therapy within 9 months prior to randomization;~* The participant had Type 2 or 3 Gaucher disease or was suspected of having Type 3 Gaucher disease;~* The participant had any clinically significant disease, other than Gaucher disease, including cardiovascular, renal, hepatic, gastrointestinal (GI), pulmonary, neurologic, endocrine, metabolic, (for example, hypokalemia, hypomagnesemia), or psychiatric disease, other medical conditions, or serious intercurrent illness that might confound the study results, or, on the opinion of the investigator, might preclude participation in the study;~* The participant had tested positive for the human immunodeficiency virus (HIV) antibody, Hepatitis C antibody, or Hepatitis B surface antigen;~* The participant had received an investigational product within 30 days prior to randomization;~* The participant was pregnant or lactating.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active (Type: EXPERIMENTAL): Eliglustat
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced malignancies (except leukemias), histologically proven at diagnosis; Histologically confirmed advanced malignancies that are known to be sensitive to PF-03241066 inhibition, e.g. ALK, c-MET and ROS~* Solid tumors must have measurable disease (Recommended Phase 2 Dose Cohort patients with non-measurable disease may enter on a case-by-case basis); not required for DDI sub-studies.~* Adequate blood cell counts, kidney function, liver function and Eastern Cooperative Oncology Group (ECOG) score of 0 or 1 (for the Recommended Phase 2 Cohort, a ECOG score of 2 may be allowed on a case-by-case basis)~Exclusion Criteria:~* Major surgery, radiation therapy or anti-cancer therapy within 2 to 4 weeks of starting study treatment, depending on the patient cohort~* Prior stem cell transplant except of patients with neuroblastoma, lymphoma or myeloma~* Active or unstable cardiac disease or heart attack within 3 months of starting study treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Perinatal Antiretroviral Intensification for PMTCT of HIV in Late Comers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Eligibility. Pregnant women presenting at the prenatal clinics will be eligible if they are confirmed HIV-infected, intend to deliver and bring their infant to a study site for postnatal care for at least 6 months; at least 18 years old; and have given written informed consent to participate in the study, regardless of their CD4 cell count.~Maternal inclusion criteria:~* Evidence of HIV infection, as documented by two serology tests obtained at two different dates;~* All HIV infected pregnant women will be enrolled, either in the intervention arm or an observational study group.~  * Women more than 30 weeks gestational age at start of antiretroviral treatment will be eligible for the intervention. They will actually receive the study intervention if they present in labor after less than 8 weeks of treatment duration;~ * Women with no ANC will receive standard care and will be enrolled in an observational study group(and their infant will receive standard of care perinatal antiretroviral intensification)~ * Women with less than 30 weeks gestational age at start of treatment will receive standard care and will also be enrolled in the Observational Reference group;~* Agreement not to breastfeed;~* Consent to participate and to be followed for the duration of the study~Exclusion Criteria:~* Evidence of pre-existing fetal anomalies incompatible with life;~* Concurrent participation to any other clinical trial without prior agreement of the two study teams

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Perinatal intensification (Type: EXPERIMENTAL): Perinatal antiretroviral intensification (study treatment):~* Mothers: One NVP 200 mg tablet at onset of labor with continuation of HAART for four weeks postpartum~* Newborn: AZT+3TC+ NVP for 2 weeks, followed by AZT+3TC for 2 weeks~The standard of care in Thailand is defined as:~* Maternal: ZDV 300 mg, 3TC 150mg and LPV/r 400/100 twice a day starting as soon possible after 14 weeks of pregnancy + ZDV 300 mg every 3 hours during labor~* Newborn: ZDV 4 mg/kg every 12 hours for 4 weeks (ZDV dosing adjusted for premature infants).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Post-Marketing Surveillance of Prazaxa® on the Long-term Use in Patients With Nonvalvular Atrial Fibrillation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~- Patients with nonvalvular atrial fibrillation who have never received Prazaxa Capsules for preventing the occurrence of ischemic stroke and systemic embolism will be included.~Exclusion criteria:~- None

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with NVAF (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete